The Oncology Institute Francisco Gentil (Instituto Português de Oncologia Francisco Gentil) is renowned for providing comprehensive cancer care and advanced oncological services. Here are some of the specialized services offered:
Medical Oncology:
Radiation Oncology:
Surgical Oncology:
Pediatric Oncology:
Hematology:
Palliative Care:
The Instituto Português de Oncologia de Francisco Gentil (IPOFG), commonly known as the Portuguese Institute of Oncology, is a renowned healthcare institution in Portugal dedicated to the prevention, diagnosis, treatment, and research of cancer. Established in 1923, the institute has a long-standing history of providing exceptional oncological care and advancing cancer research.
Mission
IPOFG's mission is to deliver comprehensive, high-quality care to cancer patients, focusing on their physical, emotional, and social needs. The institute strives to improve patient outcomes through innovative treatments and state-of-the-art technology while promoting a multidisciplinary approach to oncology.
Vision
The vision of IPOFG is to be a national and international reference in oncological care and research. The institute aims to lead the way in developing new cancer therapies, improving patient quality of life, and contributing to global efforts in cancer control and eradication.
Core Values
The Oncology Institute Francisco Gentil (Instituto Português de Oncologia Francisco Gentil) is renowned for providing comprehensive cancer care and advanced oncological services. Here are some of the specialized services offered:
Medical Oncology:
Radiation Oncology:
Surgical Oncology:
Pediatric Oncology:
Hematology:
Palliative Care:
The Portuguese Oncology Institute Francisco Gentil (IPO), encompassing branches in Lisbon, Porto, and Coimbra, is highly regarded for its comprehensive cancer care, research, and education.
Quality and Recognition
Clinical Excellence: IPO Lisboa is a leading institution in the south of Portugal, recognized for its extensive research and high standards in cancer treatment. It has a substantial number of active clinical trials and non-interventional studies, indicating a robust engagement in advancing oncology research. The institute is well-staffed with 360 physicians and 571 nurses, ensuring a high level of care for patients​​.
Research and Innovation: IPO Porto is noted for its dedicated Early Phase Clinical Trials Unit, established in 2019, which focuses on promoting patient access to innovative treatments through clinical research. The unit specializes in early drug development and biomarker-driven clinical trials, enhancing the institution's role in cutting-edge cancer therapy​.
Accreditations and Certifications: IPO Porto is accredited by the Organization of European Cancer Institutes (OECI) as a Comprehensive Cancer Center. This accreditation underscores its commitment to high standards in cancer care and research​​.
Facilities and Services
Specialized Departments: Both IPO Lisboa and IPO Porto have specialized departments catering to various types of cancer, including pediatric oncology, esophageal cancer, testicular cancer, sarcomas, and more. These specialized units are equipped with state-of-the-art technology and facilities​​.
Vision
The Oncology Institute Francisco Gentil aims to be a leader in cancer care and research, offering world-class treatment and support services to patients while advancing the understanding and treatment of cancer through cutting-edge research and innovation.
Mission
The mission of the Oncology Institute Francisco Gentil is to provide comprehensive, patient-centered care to individuals affected by cancer. This includes prevention, diagnosis, treatment, and palliative care, all delivered with a commitment to excellence, compassion, and collaboration.
Strategic Objectives
The Oncology Institute Francisco Gentil, also known as the Portuguese Oncology Institute (IPO), has achieved significant recognition for its contributions to cancer care and research. Here are some key awards and recognitions:
ESMO Designated Centre of Integrated Oncology and Palliative Care: IPO is accredited by the European Society for Medical Oncology (ESMO) for its comprehensive cancer care and palliative services, highlighting its commitment to integrated patient care​.
OECI Accreditation: The IPO Porto branch is accredited by the Organization of European Cancer Institutes (OECI) as a Comprehensive Cancer Center. This prestigious accreditation acknowledges the institute’s excellence in cancer treatment, research, and education​ ​.
CHKS Certification: IPO Porto is certified by the CHKS (Caspe Healthcare Knowledge Systems) for its high standards in healthcare quality and patient safety. This certification underscores the institute's dedication to maintaining superior clinical and operational practices​.
ISO 9001:2008 Certification: The institute holds the ISO 9001:2008 certification, which attests to its effective quality management systems and its continuous improvement in providing cancer care services​.
Excellent Rating by FCT: The Research Center at IPO Porto (CI-IPOP) received an "Excellent" rating from the Portuguese Science Foundation (FCT) in its latest international evaluation. This recognition reflects the center's outstanding research activities and contributions to oncology​​.
These accolades demonstrate the institute's dedication to providing high-quality cancer care, advancing oncology research, and integrating palliative care to support patients comprehensively.
Read real patient testimonials of Oncology Institute Francisco Gentil and discover inspiring stories of healing, compassionate care, and life-changing experiences at our hospital.
Stay informed with the latest health tips, hospital updates, medical insights, and wellness articles curated by Oncology Institute Francisco Gentil.
Tell us what you think—leave your comments for Oncology Institute Francisco Gentil.
Leave a Comment